- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02322294
Investigating the Effects of Glucodia™ on Glucose Parameters, Triglycerides and Body Weight (14GGHF)
A Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Effects of 8 Weeks Use of Glucodia™ on Glucose Parameters, Triglycerides and Body Weight as Compared to Placebo
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5R8
- KGK Synergize Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or female adults, aged 21 to 45 years
- BMI of 25 kg/m2 to 40 kg/m2 (inclusive)
- Subjects with Fasting Plasma Glucose 5.56mmol/L to 6.94mmol/L (100mg/dL-125mg/dL) AND EITHER Fasting Insulin 60 pmol/L to 180 pmol/L OR Triglycerides 1.36mmol/L to 3.39 mmol/L (120mg/dL-300mg/dL)
- Subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation).
OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System), Double-barrier method (condoms with spermicide or diaphragm with spermacide), Non-hormonal intrauterine devices, Vasectomy of partner, Non-heterosexual lifestyle
- Subjects who have no plans to change their smoking habits during the trial period.
- Subjects who are normally active and are deemed to be healthy by the Medical Director
- Subjects who agree to maintain their current level of activity throughout the trial period.
- Subjects who agree to maintain their current dietary habits throughout the trial period.
- Subjects who have given voluntary, written, informed consent to participate in the study.
Exclusion Criteria:
- Subjects who are pregnant, breastfeeding or planning on becoming pregnant throughout the course of the study.
- Subjects with Fasting Glucose < 5.56 mmol/L or > 6.94 mmol/L
- Subjects with Fasting Plasma Glucose 5.56 mmol/L to 6.94 mmol/L who DO NOT have EITHER Fasting Insulin 60 pmol/L to 180 pmol/L OR Triglycerides 1.35 mmol/L to 3.39 mmol/L
- Subjects with BMI < 25 kg/m2 or > 40 kg/m2
- Subjects who have experienced weight loss or gain of greater than 4.5 kg (approximately 10 lbs) in the past 3 months
- Subjects with uncontrolled hypertension ( ≥ 140 mmHg)
- Subjects with any major diseases of the cardiovascular, renal, hepatic, gastrointestinal, pulmonary or endocrine systems
- History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years after diagnosis are acceptable
- Subjects with neurological disorders or significant psychiatric illnesses
- Subjects with unstable thyroid disease
- Subjects who are immuno-compromised (HIV positive, on anti-rejection medication, rheumatoid arthritis)
- Subjects who have taken any medication or natural health products intended for the management of diabetes, dyslipidemia or body weight within 3 months of randomization.
- Subjects who use illicit drugs or have a history of alcohol or drug abuse within the past 6 months
- Subjects who currently consume greater than 2 standard alcoholic drinks per day.
- Subjects who have participated in a clinical research trial within 30 days prior to randomization.
- Subjects with an allergy or sensitivity to the investigational product ingredient.
- Subjects who are cognitively impaired and/or who are unable to give informed consent
- Subjects who have abnormal laboratory results or any other medical or psychological condition which, in the opinion of the Principle Investigator, may adversely affect the subjects ability to complete the study or its measures or which may pose significant risk to the subject
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: Glucodia™
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in glucose response to 2-hour oral glucose tolerance test (OGTT) in subjects taking Glucodia™ versus Placebo
Time Frame: Baseline and week 8
|
Assessed by the change in the area under the curve in glucose response
|
Baseline and week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in insulin response to 2-hour oral glucose tolerance test (OGTT) in subjects taking Glucodia™ versus Placebo
Time Frame: Baseline and week 8
|
Assessed by the change in the area under the curve in insulin response
|
Baseline and week 8
|
Change in fasting glucose in subjects taking Glucodia™ versus Placebo
Time Frame: Baseline, week 4 and week 8
|
Baseline, week 4 and week 8
|
|
Change in fasting insulin in subjects taking Glucodia™ versus Placebo
Time Frame: Baseline, week 4 and week 8
|
Baseline, week 4 and week 8
|
|
Change in HOMA-IR in subjects taking Glucodia™ versus Placebo
Time Frame: Baseline, week 4 and week 8
|
Baseline, week 4 and week 8
|
|
Change in adiponectin levels in subjects taking Glucodia™ versus Placebo
Time Frame: Baseline, week 4 and week 8
|
Baseline, week 4 and week 8
|
|
Change in lipid panel levels in subjects taking Glucodia™ versus Placebo
Time Frame: Baseline, week 4 and week 8
|
Lipid panel includes total cholesterol, triglycerides, HDL, LDL, free fatty acids and non-esterified fatty acids
|
Baseline, week 4 and week 8
|
Change in body composition in subjects taking Glucodia™ versus Placebo
Time Frame: Baseline, week 4 and week 8
|
Assessed via DXA scan
|
Baseline, week 4 and week 8
|
Change in body composition in subjects taking Glucodia™ versus Placebo
Time Frame: Baseline, week 4 and week 8
|
Assessed via circumference measurements of the arm, thigh, hip and waist and the hip to waist ratio
|
Baseline, week 4 and week 8
|
Change in body weight in subjects taking Glucodia™ versus Placebo
Time Frame: Baseline, week 4 and week 8
|
Baseline, week 4 and week 8
|
|
Change in appetite in subjects taking Glucodia™ versus Placebo
Time Frame: Baseline, week 4 and week 8
|
Assessed using a Satiety VAS scale questionnaire
|
Baseline, week 4 and week 8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Vital Signs in subjects taking Glucodia™ versus Placebo
Time Frame: Screening, Baseline, week 4, week 8
|
Blood Pressure and Heart Rate
|
Screening, Baseline, week 4, week 8
|
Changes in Blood Hematology and Clinical Chemistry in subjects taking Glucodia™ versus Placebo
Time Frame: Screening, Baseline, week 4 and week 8
|
CBC, electrolytes, creatinine, AST, ALT, GGT, bilirubin, HbA1c, BUN, total protein, albumin, globulin and calcium
|
Screening, Baseline, week 4 and week 8
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14GGHF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Body Weight
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)RecruitingWeight Loss | Weight, BodyUnited States
-
Oslo University HospitalMayo Clinic; Sorlandet Hospital HF; The Hospital of Vestfold; University of TwenteActive, not recruiting
-
Fred Hutchinson Cancer CenterCompletedWeight Loss | Weight, BodyUnited States
-
Pusan National University HospitalCompletedWeight Change, Body
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting
-
Erik Ramirez LopezCompletedWeight Loss | Body CompositionMexico
-
University of LeedsDietary Assessment LtdRecruitingWeight Loss | Colorectal Surgery | Weight Change, Body | Gastroenterology SurgeryUnited Kingdom
-
University of TennesseeMayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases...CompletedSmoking Cessation | Weight Change, BodyUnited States
-
Virta HealthActive, not recruiting
-
University of CopenhagenCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States